Fig. 3: The efficacy of subsequent TKIs in accordance with their mutational status. | BJC Reports

Fig. 3: The efficacy of subsequent TKIs in accordance with their mutational status.

From: Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors

Fig. 3

a Swimmer plot of treatment duration and clinical outcome in accordance with mutational status matched or unmatched to subsequent therapy: swimmer plot depicted treatment duration and clinical outcomes for patients receiving TKIs matched to their mutational status (top section) and those treated with non-matched TKIs (bottom section). Disease status at treatment initiation, therapeutic agents used, and continuity of treatment are indicated for each patient. b Progression-free survival in accordance with the suitability of TKIs for KIT or PDGFRA mutations: patients treated with TKIs matched to their specific KIT or PDGFRA mutation profiles exhibited significantly longer PFS compared to those who received mismatched TKIs.

Back to article page